Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ: VSTM )

3.710 -0.230 (-5.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,113,400
Open 3.920
Bid (Size) 3.640 (3)
Ask (Size) 3.750 (2)
Prev. Close 3.940
Today's Range 3.710 - 4.010
52wk Range 2.100 - 14.22
Shares Outstanding 44,506,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
From Applied Therapeutics
Via GlobeNewswire
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
From Verastem Oncology
Via Business Wire

Performance

YTD
-55.30%
-55.30%
1 Month
-18.82%
-18.82%
3 Month
+37.92%
+37.92%
6 Month
+24.50%
+24.50%
1 Year
-55.14%
-55.14%

More News

Read More
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology to Participate in Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting
From Verastem Oncology
Via Business Wire
Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024
From Verastem Oncology
Via Business Wire
VSTM Stock Earnings: Verastem Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
From Verastem Oncology
Via Business Wire
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
From Verastem Oncology
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Verastem, Helios, and LegalZoom and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
From Verastem Oncology
Via Business Wire
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.